Literature DB >> 1802693

In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis.

L Herwaldt1, L Boyken, M Pfaller.   

Abstract

The purpose of the study was to determine whether vancomycin-resistant strains of Staphylococcus haemolyticus could be selected regardless of the initial MIC of vancomycin. Twenty-one bloodstream isolates of Staphylococcus haemolyticus were studied by broth and agar selection methods. The broth method selected strains for which MICs of vancomycin ranged from 4 to 32 micrograms/ml and MBCs from 16 to greater than 128 micrograms/ml. The agar method selected strains for which MICs ranged from 8 to 32 micrograms/ml and MBCs from 8 to greater than 128 micrograms/ml. For comparison, seven strains of Staphylococcus epidermidis were evaluated by the agar selection method. Final MICs of vancomycin ranged from 8 to 16 micrograms/ml; MBCs ranged from 16 to 64 micrograms/ml. Clearly, in vitro exposure to vancomycin can select strains of Staphylococcus haemolyticus and Staphylococcus epidermidis for which MIC values are beyond the susceptible breakpoint.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1802693     DOI: 10.1007/BF01984921

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay.

Authors:  M A Martin; M A Pfaller; R P Wenzel
Journal:  Ann Intern Med       Date:  1989-01-01       Impact factor: 25.391

2.  Pharmacist interventions to improve prescribing of vancomycin and tobramycin.

Authors:  C V Fletcher; R M Giese; J H Rodman
Journal:  Am J Hosp Pharm       Date:  1986-09

3.  Retrospective evaluation of vancomycin use in a university hospital.

Authors:  J Nightingale; B W Chaffee; C L Colvin; M R Alexander; T Rice; M B Ross
Journal:  Am J Hosp Pharm       Date:  1987-08

4.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

5.  In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.

Authors:  C Watanakunakorn
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

6.  Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection.

Authors:  L A Veach; M A Pfaller; M Barrett; F P Koontz; R P Wenzel
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

7.  Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci.

Authors:  R M Blumenthal; R Raeder; C D Takemoto; E H Freimer
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

8.  Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus.

Authors:  R S Schwalbe; W J Ritz; P R Verma; E A Barranco; P H Gilligan
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

9.  Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus.

Authors:  J W Froggatt; J L Johnston; D W Galetto; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

  9 in total
  15 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.

Authors:  B E Domaracki; A M Evans; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades.

Authors:  E Ahlstrand; K Svensson; L Persson; U Tidefelt; B Söderquist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-05       Impact factor: 3.267

Review 5.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

6.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

7.  Presence of UDP-N-acetylmuramyl-hexapeptides and -heptapeptides in enterococci and staphylococci after treatment with ramoplanin, tunicamycin, or vancomycin.

Authors:  D Billot-Klein; D Shlaes; D Bryant; D Bell; R Legrand; L Gutmann; J van Heijenoort
Journal:  J Bacteriol       Date:  1997-08       Impact factor: 3.490

8.  Cloning of the Staphylococcus aureus ddh gene encoding NAD+-dependent D-lactate dehydrogenase and insertional inactivation in a glycopeptide-resistant isolate.

Authors:  S Boyle-Vavra; B L de Jonge; C C Ebert; R S Daum
Journal:  J Bacteriol       Date:  1997-11       Impact factor: 3.490

Review 9.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  Vancomycin resistance in staphylococci.

Authors:  Arjun Srinivasan; James D Dick; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.